Search research articles
Contact Us
Filters
Showing results (351-360 of 368) with videos related to
Page
of 37
Sort By:
Journal of Hematology & Oncology
|
August 18, 2022
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Qian Jiang, Zongru Li, Yazhen Qin, et al.
Journal of Hematology & Oncology
|
February 21, 2023
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Qian Jiang, Zongru Li, Yazhen Qin, et al.
Journal of Hematology & Oncology
|
September 1, 2024
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial
Jing Lu, Huiying Qiu, Ying Wang, et al.
Cell Reports
|
October 15, 2013
An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis
Jijun Cheng, Shangqin Guo, Suning Chen, et al.
Blood
|
July 21, 2023
Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML
Jundan Xie, Xiebing Bao, Sheng-Li Xue, et al.
Experimental Hematology & Oncology
|
June 21, 2023
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera
Jie Jin, Lei Zhang, Albert Qin, et al.
Haematologica
|
November 27, 2025
Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter study
Mingkai Shu, Wenjing Ding, Linlin Wang, et al.
Transplantation and Cellular Therapy
|
April 26, 2026
Multicenter Analysis of Transplant Outcomes for the Newly Defined MDS/AML Entity in the 2022 ICC: Risk Stratification and Comparison with AML
Yuhua Ru, Mimi Xu, Mengqi Xiang, et al.
Journal of Hematology & Oncology
|
April 2, 2022
Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells
Jingwen Tan, Yujie Jia, Meixia Zhou, et al.
Genome Research
|
December 2, 2016
Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP
Maoxiang Qian, Hui Zhang, Shirley Kow-Yin Kham, et al.
Page
of 37
Search research articles
Search
Showing results (351-360 of 368) with videos related to
Sort By:
Page
of 37
Journal of Hematology & Oncology
|
August 18, 2022
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Qian Jiang, Zongru Li, Yazhen Qin, et al.
Journal of Hematology & Oncology
|
February 21, 2023
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Qian Jiang, Zongru Li, Yazhen Qin, et al.
Journal of Hematology & Oncology
|
September 1, 2024
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial
Jing Lu, Huiying Qiu, Ying Wang, et al.
Cell Reports
|
October 15, 2013
An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis
Jijun Cheng, Shangqin Guo, Suning Chen, et al.
Blood
|
July 21, 2023
Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML
Jundan Xie, Xiebing Bao, Sheng-Li Xue, et al.
Experimental Hematology & Oncology
|
June 21, 2023
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera
Jie Jin, Lei Zhang, Albert Qin, et al.
Haematologica
|
November 27, 2025
Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter study
Mingkai Shu, Wenjing Ding, Linlin Wang, et al.
Transplantation and Cellular Therapy
|
April 26, 2026
Multicenter Analysis of Transplant Outcomes for the Newly Defined MDS/AML Entity in the 2022 ICC: Risk Stratification and Comparison with AML
Yuhua Ru, Mimi Xu, Mengqi Xiang, et al.
Journal of Hematology & Oncology
|
April 2, 2022
Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells
Jingwen Tan, Yujie Jia, Meixia Zhou, et al.
Genome Research
|
December 2, 2016
Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP
Maoxiang Qian, Hui Zhang, Shirley Kow-Yin Kham, et al.
Page
of 37